Rhumbline Advisers Boosts Holdings in IDEAYA Biosciences, Inc. $IDYA

Key Points

• Rhumbline Advisers increased its stake in IDEAYA Biosciences by 9.6% during the first quarter, holding 124,437 shares valued at approximately $2.04 million.
• Several institutional investors, including Millennium Management and Royal Bank of Canada, significantly boosted their positions in IDEAYA Biosciences, showcasing strong institutional interest.
• Analysts have provided a consensus target price of $42.85 for IDEAYA Biosciences, with a majority rating it as a "Moderate Buy."

Rhumbline Advisers increased its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 9.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 124,437 shares of the company's stock after purchasing an additional 10,876 shares during the quarter. Rhumbline Advisers owned 0.14% of IDEAYA Biosciences worth $2,038,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in IDEAYA Biosciences by 9.1% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 7,483 shares of the company's stock valued at $123,000 after acquiring an additional 627 shares during the period. Swiss National Bank lifted its holdings in IDEAYA Biosciences by 0.8% in the first quarter. Swiss National Bank now owns 150,800 shares of the company's stock valued at $2,470,000 after acquiring an additional 1,200 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of IDEAYA Biosciences by 6.0% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,301 shares of the company's stock worth $349,000 after buying an additional 1,214 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in shares of IDEAYA Biosciences by 180.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company's stock worth $39,000 after buying an additional 1,546 shares during the last quarter. Finally, CWM LLC raised its stake in shares of IDEAYA Biosciences by 325.7% during the 1st quarter. CWM LLC now owns 2,371 shares of the company's stock worth $39,000 after buying an additional 1,814 shares during the last quarter. Institutional investors and hedge funds own 98.29% of the company's stock.

IDEAYA Biosciences Stock Performance

IDEAYA Biosciences stock traded down $0.48 during midday trading on Friday, reaching $25.74. 1,973,349 shares of the company were exchanged, compared to its average volume of 1,220,327. The company has a market capitalization of $2.26 billion, a price-to-earnings ratio of -6.79 and a beta of 0.12. The firm's 50-day simple moving average is $24.24 and its 200-day simple moving average is $20.95. IDEAYA Biosciences, Inc. has a 1 year low of $13.45 and a 1 year high of $36.64.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.03). The company had revenue of $6.00 million during the quarter, compared to analysts' expectations of $3.48 million. The company's quarterly revenue was up NaN% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.68) EPS. On average, analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on IDYA. Wells Fargo & Company began coverage on IDEAYA Biosciences in a research note on Thursday, June 26th. They set an "overweight" rating and a $44.00 price target for the company. Royal Bank Of Canada lifted their price target on IDEAYA Biosciences from $36.00 to $38.00 and gave the stock an "outperform" rating in a research note on Tuesday, September 9th. Citizens Jmp began coverage on IDEAYA Biosciences in a research note on Thursday, September 4th. They set a "mkt outperform" rating and a $41.00 price target for the company. Barclays began coverage on IDEAYA Biosciences in a research note on Thursday, September 4th. They set an "overweight" rating and a $40.00 price target for the company. Finally, Oppenheimer set a $36.00 price target on IDEAYA Biosciences and gave the stock an "outperform" rating in a research note on Monday, September 8th. Fourteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $43.36.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.